Funders › CT › Rett Syndrome Research Trust Inc › 2019
Grants paid by Rett Syndrome Research Trust Inc, tax year 2019
EIN 26-0687439 · Trumbull, CT · Form 990, Schedule I · NTEE E12
In tax year 2019, Rett Syndrome Research Trust Inc (EIN 26-0687439) reported 18 grants paid totaling $6,719,945. Dataset version 2026.09.0, built 2026-09-03.
Every grant, 2019
| Tax year | Recipient | Match | Amount | Type | Purpose | Source filing |
|---|---|---|---|---|---|---|
| 2019 | Gene Therapy Consortium | U | $1,480,816 | paid | GENE THERAPY CONSORTIUM | 202002529349300655 |
| 2019 | University of Massashussets Amherst, MA | A | $891,120 | paid | RNA EDITING AND DNA EDITING AS THERAPEUTIC STRATEGY TO TREAT RETT ENHANCING READTHROUGH CAPABILITY FOR NONSENSE MUTATIONS. DEVELOPMENT OF SIRNA COMPOUNDS TO TREAT DUPLICATION SYNDROME. | 202002529349300655 |
| 2019 | Massachusetts Institute of Technology Cambridge, MA | A | $777,332 | paid | RNA EDITING AS THERAPEUTIC STRATEGY TO TREAT RETT. | 202002529349300655 |
| 2019 | Ombd Consortium | U | $619,186 | paid | OMBD CONSORTIUM | 202002529349300655 |
| 2019 | Harvard University Boston, MA | A | $514,195 | paid | REACTIVATING SILENT MECP2 DRUG SCREENING MECP2 FUNCTION | 202002529349300655 |
| 2019 | Oregon Health and Sciences University Foundation Portland, OR | A | $495,423 | paid | MECP2 CONSORTIUM | 202002529349300655 |
| 2019 | Clinical Trial Consortium | U | $306,634 | paid | CLINICAL TRIAL CONSORTIUM | 202002529349300655 |
| 2019 | Case Western Reserve University Cleveland, OH | A | $279,978 | paid | PRE-CLINICAL TESTING OF KETAMINE COMPOUNDS | 202002529349300655 |
| 2019 | Baylor College of Medicine Houston, TX | A | $223,391 | paid | PRECLINICAL DRUG DEVELOPMENT | 202002529349300655 |
| 2019 | University of California at San Diego La Jolla, CA | A | $215,471 | paid | IDENTIFICATION OF MODIFIER GENES THAT SUPPRESS THE EFFECTS OF MECP2 MUTATIONS | 202002529349300655 |
| 2019 | Whitehead Institute of Biomedical Research Cambridge, MA | A | $214,950 | paid | DRUG TESTING | 202002529349300655 |
| 2019 | Mecp2 Consortium | U | $187,994 | paid | MECP2 CONSORTIUM | 202002529349300655 |
| 2019 | Yale University New Haven, CT | A | $157,972 | paid | PROTEIN REPLACEMENT AS A THERAPEUTIC IMPROVING DELIVERY PLATFORMS | 202002529349300655 |
| 2019 | Other | U | $112,653 | paid | BURDEN OF ILLNESS STUDY PROTEIN REPLACEMENT AS A THERAPEUTIC PROCEDURE | 202002529349300655 |
| 2019 | Rett Syndrome Center at Montefiore Medical Center Bronx, NY | A | $75,000 | paid | COPAXONE SUPPLEMENT | 202002529349300655 |
| 2019 | Improving Delivery Platform | U | $59,000 | paid | IMPROVING DELIVERY PLATFORM | 202002529349300655 |
| 2019 | Fred Hutchinson Cancer Research Center Seattle, WA | A | $58,000 | paid | REACTIVATING SILENT MECP2 BNT CONFIRMATION | 202002529349300655 |
| 2019 | Nationwide Children's Hospital Columbus, OH | A | $50,830 | paid | GENE THERAPY CONSORTIUM | 202002529349300655 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Recipient matching for this dataset version has not yet completed its independent precision check. Tier A rows carry the EIN the filer reported; tiers B–D are the matcher's inference and should be read as leads until the check is published on the methodology page.
Derived from IRS Form 990 e-file XML. Dataset version 2026.09.0, built 2026-09-03. All years for this funder.
The same organization elsewhere in the program: exempt status and filing health · federal awards · grant guidance · open opportunities.
This is informational only, derived from public data on the dates shown. It is not an eligibility determination, and not legal, tax, or accounting advice. Verify against the official source before relying on it.